Hudson Executive Intends to Engage in Discussions with AtriCure
January 24, 2017 at 07:31 am EST
Share
On January 24, 2017, Hudson Executive Capital LP announced that it had discussions with AtriCure, Inc.’s management and members of the board of directors of the Company to discuss the Company’s business, strategies and corporate governance. In addition, Hudson Executive stated that it has found its conversations to date with the Board and management to be constructive, and may seek to have additional conversations with the management, Board, stockholders of the Company, and other persons to discuss the Company’s business, strategies, corporate governance, and other matters related to the Company.
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.